Type 2 Diabetes | OMICS International | Endocrinology And Metabolic Syndrome

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Type 2 Diabetes

Type 2 diabetes results from the progressive alteration of the endocrine function (insulin secretory) of the pancreatic beta cells as well as pancreatic endocrine inability to compensate peripheral insulin resistance. It is a chronic and progressive pathology that requires a lifetime monitoring and surveillance with a therapeutic scaling, regarding the drug therapy. Incretins are a new class of drugs that enriches the therapeutic arsenal already available to treat type 2 diabetes which is not fully satisfactory because it does not affect weight loss nor improves β cells function. Incretins are a promising therapeutic option because they improve glycemic control, induce weight loss of about 2-3 kg/year and offer the hope of a stabilization or improvement of β cells function by promoting proliferation and inhibiting apoptosis of β cells. Position of Incretin Agents in the Traitement of Type 2 Diabetes Mellitus: Literature Review :Sara Deghima, Smina Yahiaoui and Aissa Boudiba
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on April, 2021